Pharmacoeconomic review report: Empagliflozin (Jardiance)

Empagliflozin (Jardiance) is a once-daily oral antidiabetic drug belonging to the sodium glucose cotransporter-2 (SGLT-2) inhibitor class. It promotes urinary glucose excretion. This review by the CADTH Common Drug Review (CDR) will focus on the following indication: 1. For adults with type 2 diabet...

Full description

Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH October 2015, 2015
Series:CADTH common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:Empagliflozin (Jardiance) is a once-daily oral antidiabetic drug belonging to the sodium glucose cotransporter-2 (SGLT-2) inhibitor class. It promotes urinary glucose excretion. This review by the CADTH Common Drug Review (CDR) will focus on the following indication: 1. For adults with type 2 diabetes mellitus, to improve glycemic control in combination with metformin and a sulfonylurea when diet, exercise, and dual therapy (with metformin plus sulfonylurea) do not provide adequate glycemic control. The recommended dose of empagliflozin is 10 mg once daily. This dose can be increased to 25 mg once daily in patients who tolerate empagliflozin but need additional glycemic control. The manufacturer submitted a price of $2.6177 per 10 mg or 25 mg tablet ($2.62 daily). The manufacturer is requesting a listing in a manner similar to other SGLT-2 inhibitors and/or dipeptidyl peptidase (DPP)-4 inhibitors
Physical Description:1 PDF file (ii, 13 pages)